Part­nered with Gilead and Sanofi, pro­tein degra­da­tion spe­cial­ist Nurix bags $120M to chart its own clin­i­cal path

The race to steer the first pro­tein degra­da­tion drugs to the clin­ic is on.

On the same day that Cam­bridge, MA-based Kymera Ther­a­peu­tics un­veiled a $102 mil­lion round to en­ter in­to de­vel­op­ment phase, Nurix said it has raised $120 mil­lion to do the same out of San Fran­cis­co’s Mis­sion Bay.

Fore­site Cap­i­tal led the round. Red­mile Group, a co-leader in Kymera’s Se­ries C, par­tic­i­pat­ed along­side Bain Cap­i­tal Life Sci­ences, Box­er Cap­i­tal (Tavi­s­tock Group), EcoR1 Cap­i­tal, Welling­ton Man­age­ment Com­pa­ny and an undis­closed in­vestor, as well as found­ing in­vestors The Col­umn Group and Third Rock Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER